19 completed. 19 Phase 3, 1 Phase 2.
By phase and status
Follow Bendamustine: new trials by email Literature Review of Bendamustine trials Research Report on Bendamustine
Trials (filtered) newest first · largest first
All 19 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation
Obinutuzumab, Venetoclax, Fludarabine - Chronic Lymphocytic Leukemia (CLL) | Phase 3 | Completed | 166 | 2020-05-28 | 2026-03-03 |
Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL
Oral azacitidine, Romidepsin, Bendamustine - Relapsed Angioimmunoblastic T-Cell Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma | Phase 3 | Completed | 86 | 2018-11-09 | 2026-04-23 |
A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy
Obinutuzumab, Bendamustine, Venetoclax - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 3 | Completed | 120 | 2018-08-10 | 2024-08-06 |
Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation
Fludarabine, Cyclophosphamide, Rituximab - Chronic Lymphocytic Leukemia | Phase 3 | Completed | 926 | 2016-12-13 | 2024-12-30 |
A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Bendamustine, Venetoclax, Rituximab - Chronic Lymphocytic Leukemia | Phase 3 | Completed | 389 | 2014-03-17 | 2023-10-17 |
A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma
Bendamustine, Rituximab, Cyclophosphamide - Lymphoma | Phase 3 | Completed | 403 | 2014-01-31 | 2025-05-25 |
A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia
Bendamustine, Chlorambucil, Cyclophosphamide - Chronic Lymphocytic Leukemia | Phase 3 | Completed | 979 | 2013-11-04 | 2019-10-28 |
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)
Rituximab, Cyclophosphamide, Vincristine - Lymphoma | Phase 3 | Completed | 159 | 2013-07-31 | 2020-08-13 |
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
Bendamustine, Rituximab, Ibrutinib - Mantle Cell Lymphoma | Phase 3 | Completed | 523 | 2013-05-16 | 2025-07-08 |
A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a
Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP), Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP), Bendamustine - Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma | Phase 3 | Completed | 743 | 2012-12-01 | 2018-01-23 |
Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma
R-CHOP or R-bendamustine, Observation, Maintenance weekly x4 - Follicular Non-Hodgkin's Lymphoma | Phase 3 | Completed | 807 | 2012-07-01 | 2022-06-21 |
Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )
Idelalisib, Rituximab, Bendamustine - Chronic Lymphocytic Leukemia | Phase 3 | Completed | 416 | 2012-06-15 | 2020-03-10 |
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Obinutuzumab, Cyclophosphamide, Doxorubicin - Non-Hodgkin's Lymphoma | Phase 3 | Completed | 1401 | 2011-07-06 | 2022-08-11 |
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Obinutuzumab, Bendamustine - Non-Hodgkin's Lymphoma | Phase 3 | Completed | 413 | 2010-04-30 | 2020-01-13 |
Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)
Bendamustine, Rituximab - Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma | Phase 3 | Completed | 54 | 2010-02-01 | 2014-04-24 |
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study
bendamustine, rituximab, vincristine - Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma | Phase 3 | Completed | 447 | 2009-04-30 | 2018-02-05 |
FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia
Rituximab, Bendamustine, Cyclophosphamide - Chronic Lymphocytic Leukemia | Phase 3 | Completed | 564 | 2008-10-02 | 2024-12-31 |
Bendamustine Plus Rituximab Versus CHOP Plus Rituximab
Bendamustine, Standard chemotherapy CHOP + Ritiximab - Non-Hodgkin Lymphomas, Follicular Lymphomas | Phase 3 | Completed | 549 | 2004-01-01 | 2024-08-22 |
Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL)
bendamustine, Fludarabine - Chronic Lymphocytic Leukemia | Phase 2 / Phase 3 | Completed | 96 | 2001-09-01 | 2011-08-25 |
Conditions studied
Leukemia, Lymphocytic, Chronic, B-Cell (9) · Lymphoma, Non-Hodgkin (5) · Lymphoma, Follicular (4) · Lymphoma, Mantle-Cell (3) · Lymphoma (2) · Chromosome 17 deletion (1) · Immunoblastic Lymphadenopathy (1) · Leukemia (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Large B-Cell, Diffuse (1) · Neoplasms (1) · Recurrence (1) · Tumor Lysis Syndrome (1)
Sponsors
Hoffmann-La Roche (6) · German CLL Study Group (2) · Janssen Research & Development, LLC (2) · AbbVie (1) · Cephalon (1) · Fondazione Italiana Linfomi - ETS (1) · Genentech, Inc. (1) · Gilead Sciences (1) · Teva Branded Pharmaceutical Products R&D, Inc. (1) · The Lymphoma Academic Research Organisation (1) · University of Giessen (1) · WiSP Wissenschaftlicher Service Pharma GmbH (1)
Countries
Germany (11) · United States (10) · Australia (9) · Belgium (9) · Canada (9) · France (9) · Italy (9) · Spain (8) · Sweden (8) · Russia (7) · United Kingdom (7) · Austria (5) · Brazil (5) · Czechia (5) · Hungary (5)
Top investigators
Barbara Eichhorst, MD (1) · Barbara Eichhorst, MD, Prof. (1) · Donato Mannina, MD (1) · Massimo Federico, MD (1) · Mathias Rummel, Dr. (1) · Norbert Niederle, Prof, MD (1)
Results publications
PMID 23433739, PMID 24591201, PMID 26239087, PMID 26875824, PMID 27233802, PMID 27345636, PMID 27695295, PMID 28031173, PMID 28976863, PMID 29562156, PMID 29584548, PMID 29749403, PMID 29856692, PMID 30309758, PMID 30341058, PMID 30523712, PMID 30811293, PMID 31050355, PMID 31053601, PMID 31455851, PMID 31462735, PMID 31729982, PMID 32314038, PMID 32601378, PMID 32986498, PMID 33605445, PMID 34323957, PMID 34709880, PMID 35194005, PMID 35605176, PMID 35657079, PMID 35829925, PMID 36379880, PMID 37163621, PMID 37172204, PMID 37722354, PMID 37957542, PMID 38096461, PMID 38620092, PMID 38796193, PMID 38821083, PMID 40009494, PMID 40106688, PMID 41770817, PMID 41879719, PMID 41911073, PMID 42837320
NIH funding
2009 (1), 2015 (1), 2019 (1), 2023 (1)